EZH2 Inhibitor Combination Therapy for Small Cell Lung Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies are inadequate for effectively treating small cell lung cancer, particularly in cases of extensive stage disease, due to high resistance and limited treatment options that do not address the role of EZH2 overexpression.
Innovation Solution
A combination therapy comprising an EZH2 inhibitor and a platinum-based antineoplastic agent, such as cisplatin or carboplatin, is administered to target and inhibit EZH2 activity, enhancing the treatment efficacy for small cell lung cancer, including refractory and relapsed cases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If platinum-based antineoplastic agents are used to treat small cell lung cancer, then initial response rate is improved, but treatment resistance develops rapidly leading to relapse
Solution Approach 1:
The patent combines platinum-based antineoplastic agents with EZH2 inhibitors in a combination therapy regimen. This merging of two different therapeutic mechanisms addresses both the initial tumor control (platinum agent) and the prevention of resistance/relapse (EZH2 inhibitor), thereby extending the duration of treatment efficacy while maintaining initial response rates.
Solution Approach 2:
The patent changes the therapeutic parameter by introducing EZH2 inhibition alongside platinum-based therapy. This parameter change targets the epigenetic regulation mechanism that drives chemoresistance in SCLC, transforming the treatment approach from solely cytotoxic to include epigenetic modulation, thus preventing the development of treatment resistance.
2Reliability
If conventional chemotherapy is used for extensive stage small cell lung cancer, then some tumor control is achieved, but treatment options are limited and efficacy is inadequate
Solution Approach 1:
The patent merges conventional chemotherapy (platinum-based agents) with targeted EZH2 inhibition to create a new combination therapy regimen. This provides both tumor control through cytotoxic effects and enhanced efficacy through epigenetic modulation, thereby expanding treatment options for extensive stage SCLC while maintaining reliable tumor control.
Solution Approach 2:
The patent creates a composite therapeutic approach by combining two different drug classes (platinum-based antineoplastic agents and EZH2 inhibitors) into a unified treatment regimen. This composite therapy leverages the strengths of both agents to achieve superior tumor control and expanded treatment versatility compared to conventional monotherapy.
3Reliability
If EZH2 inhibitor monotherapy is used, then EZH2 activity is inhibited, but treatment efficacy is insufficient compared to combination therapy
Solution Approach 1:
The patent combines EZH2 inhibitor monotherapy with platinum-based antineoplastic agents to create a synergistic combination regimen. This merging achieves both reliable EZH2 inhibition (maintaining the benefit of targeted therapy) and enhanced overall treatment efficacy (through the additive/c synergistic effects of platinum-based cytotoxicity), thereby resolving the limitation of insufficient efficacy when using EZH2 inhibitors alone.
Data Source
AI summary
This invention relates to combination therapies comprising an EZH2 inhibitor and a chemotherapeutic agent, and associated pharmaceutical compositions, methods of treatment, and pharmaceutical uses.